@article{8d644029d3d24e9d804a6eb86613c2c1,
title = "Atrial fibrillation, cognitive impairment, and neuroimaging",
abstract = "Introduction The objective of our study was to investigate cross-sectional associations of atrial fibrillation with neuroimaging measures of cerebrovascular disease and Alzheimer's disease and their interactions with mild cognitive impairment (MCI). Methods Magnetic resonance imaging scans of individuals from a population-based study were analyzed for infarctions, total gray matter, and hippocampal and white matter hyperintensity volumes. A subsample underwent positron emission tomography imaging. Results Atrial fibrillation was associated with infarctions and lower total gray matter volume. Compared with subjects with no atrial fibrillation and no infarction, the odds ratio (95% confidence intervals) for MCI was 2.99 (1.57-5.70; P =.001) among participants with atrial fibrillation and infarction, 0.90 (0.45-1.80; P =.77) for atrial fibrillation and no infarction, and 1.50 (0.96-2.34; P =.08) for no atrial fibrillation and any infarction. Discussion Participants with both atrial fibrillation and infarction are more likely to have MCI than participants with either infarction or atrial fibrillation alone.",
keywords = "Alzheimer's disease, Atrial fibrillation, Cerebrovascular disease, Mild cognitive impairment, Stroke",
author = "Jonathan Graff-Radford and Malini Madhavan and Prashanthi Vemuri and Rabinstein, {Alejandro A.} and Cha, {Ruth H.} and Mielke, {Michelle M.} and Kejal Kantarci and Val Lowe and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.} and Roberts, {Rosebud O.}",
note = "Funding Information: This work was supported in part by grants U01 AG06786 ( Mayo Clinic Study of Aging ) and P50 AG016574 ( Mayo Alzheimer Center ), and by funds from the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. Funding Information: P.V. receives research support from the NIH (R00 AG037573, P50 AG016574). M.M.M. has provided consulting services for AbbVie and Lilly and receives research support from the NIH (U01 AG06786, U01 37526) and the Michael J. Fox Foundation. K.K. serves on the data safety monitoring boards for Pfizer Inc and Janssen Alzheimer Immunotherapy, Takeda Global Research & Development Center, Inc and receives research support from the NIH (R01-AG40042, P50-AG016574, P50-AG44170, U19-AG10483, and U01-AG04279) and the MN Partnership for Biotechnology and Medical Genomics. V.L. is a consultant for Bayer Schering Pharma and Piramal Imaging and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH, the Elsie and Marvin Dekelboum Family Foundation, the MN Partnership for Biotechnology and Medical Genomics, and the Leukemia and Lymphoma Society. D.S.K. serves as deputy editor for Neurology; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer's Disease Treatment Unit. He is an investigator in clinical trials sponsored by TauRx and receives research support from the NIH (R01-AG11378, P50 AG16574, U01 AG06786, AG 29550, AG32306, and U01 96917). R.C.P. serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare and receives research support from the NIH (P50-AG16574, U01-AG06786, R01-AG11378, and U01–24904). C.R.J. has provided consulting services for Janssen Research and Development and Eli Lilly. He receives research funding from the US National Institutes of Health (NIH; R01-AG011378, U01-HL096917, U01-AG024904, RO1 AG041851, R01 AG37551, R01AG043392, and U01-AG06786) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. Funding Information: AcknowledgmentsThis work was supported in part by grants U01 AG06786 (Mayo Clinic Study of Aging) and P50 AG016574 (Mayo Alzheimer Center), and by funds from the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. Publisher Copyright: {\textcopyright} 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = apr,
day = "1",
doi = "10.1016/j.jalz.2015.08.164",
language = "English (US)",
volume = "12",
pages = "391--398",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",
}